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Abstract
Introduction: Coronavirus disease 2019 (COVID-19) has caused >3.5 million deaths
worldwide and affected >160 million people. At least twice as many have been infected
but remained asymptomatic or minimally symptomatic. COVID-19 includes central
nervous system manifestations mediated by inflammation and cerebrovascular, anoxic,
and/or viral neurotoxicity mechanisms. More than one third of patients with COVID19 develop neurologic problems during the acute phase of the illness, including loss
of sense of smell or taste, seizures, and stroke. Damage or functional changes to the
brain may result in chronic sequelae. The risk of incident cognitive and neuropsychiatric complications appears independent from the severity of the original pulmonary
illness. It behooves the scientific and medical community to attempt to understand the
molecular and/or systemic factors linking COVID-19 to neurologic illness, both short
and long term.
Methods: This article describes what is known so far in terms of links among COVID19, the brain, neurological symptoms, and Alzheimer’s disease (AD) and related
dementias. We focus on risk factors and possible molecular, inflammatory, and viral
mechanisms underlying neurological injury. We also provide a comprehensive description of the Alzheimer’s Association Consortium on Chronic Neuropsychiatric Sequelae
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of SARS-CoV-2 infection (CNS SC2) harmonized methodology to address these
questions using a worldwide network of researchers and institutions.
Results: Successful harmonization of designs and methods was achieved through a
consensus process initially fragmented by specific interest groups (epidemiology, clinical assessments, cognitive evaluation, biomarkers, and neuroimaging). Conclusions
from subcommittees were presented to the whole group and discussed extensively.
Presently data collection is ongoing at 19 sites in 12 countries representing Asia,
Africa, the Americas, and Europe.
Discussion: The Alzheimer’s Association Global Consortium harmonized methodology
is proposed as a model to study long-term neurocognitive sequelae of SARS-CoV-2
infection.
KEYWORDS

cognitive impairment, dementia, neuropsychiatric sequelae, predictors, SARS-CoV-2

Key Points
∙ The following review describes what is known so far in terms of molecular and epidemiological links among COVID-19, the brain, neurological symptoms, and AD and
related dementias (ADRD)
∙ The primary objective of this large-scale collaboration is to clarify the pathogenesis of ADRD and to advance our understanding of the impact of a neurotropic virus
on the long-term risk of cognitive decline and other CNS sequelae. No available
evidence supports the notion that cognitive impairment after SARS-CoV-2 infection is a form of dementia (ADRD or otherwise). The longitudinal methodologies
espoused by the consortium are intended to provide data to answer this question
as clearly as possible controlling for possible confounders. Our specific hypothesis
is that SARS-CoV-2 triggers ADRD-like pathology following the extended olfactory
cortical network (EOCN) in older individuals with specific genetic susceptibility.
∙ The proposed harmonization strategies and flexible study designs offer the possibility to include large samples of under-represented racial and ethnic groups, creating
a rich set of harmonized cohorts for future studies of the pathophysiology, determinants, long-term consequences, and trends in cognitive aging, ADRD, and vascular
disease.
∙ We provide a framework for current and future studies to be carried out within the
Consortium. and offers a “green paper” to the research community with a very broad,
global base of support, on tools suitable for low- and middle-income countries aimed
to compare and combine future longitudinal data on the topic.
∙ The Consortium proposes a combination of design and statistical methods as a
means of approaching causal inference of the COVID-19 neuropsychiatric sequelae.
We expect that deep phenotyping of neuropsychiatric sequelae may provide a series
of candidate syndromes with phenomenological and biological characterization that
can be further explored. By generating high-quality harmonized data across sites we
aim to capture both descriptive and, where possible, causal associations.
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1

1.2
Evidence of lingering cognitive impairment
after SARS-CoV-2 infection

INTRODUCTION

1.1

SARS-CoV-2 and the brain
There is significant evidence supporting a connection between cog-

Coronavirus disease 2019 (COVID-19) has caused >5.6 million deaths

nitive impairment and coronavirus infection. After the coronavirus

worldwide and affected >450 million people. At least twice as many

pandemics of 2002 and 2012, 20% of recovered individuals reported

have been infected but remained asymptomatic or minimally symp-

memory impairment.38 An early report during the ongoing pandemic

tomatic. Though initially understood as a respiratory illness, COVID-19

found that one third of individuals with COVID-19 had dysexecu-

includes central nervous system (CNS) manifestations mediated by

tive syndrome at the time of hospital discharge.38 Impaired cognitive

inflammation, and cerebrovascular, anoxic, and/or viral neurotoxicity

abilities lead to poor occupational and functional outcomes, but the

mechanisms.1 More than one third of patients with COVID-19 expe-

extent to which cognitive deficits contribute to long-term disability

rience neurologic complications during the acute illness, including loss

in COVID-19 survivors remains unknown. Cognitive impairment can

of sense of smell or taste, seizures, and stroke. Following the acute ill-

precipitate or exacerbate existing mental health disorders, which in

ness, the risk of incident neurological or psychiatric disorder remains

turn worsen cognitive dysfunction.39,40 In a recent meta-analysis and

months.2–5

Mounting evidence indicates that

systematic review, the most common post-COVID-19 neurological

the risk of late cognitive and neuropsychiatric complications may be

symptoms were headache, nausea, vomiting, muscular pain, anosmia,

independent of the severity of the original pulmonary and systemic

and ageusia.12 The same study reported that SARS-CoV-2 infection

illness.6–16

may result in cognitive impairment even after mild or asymptomatic

elevated for at least 6

One possible account of the neurological complication of COVID-

infection.12–15 Concerningly, even asymptomatic COVID-19 individu-

19 is that the causative virus, severe acute respiratory syndrome

als had lowered scores in visuoperception, naming, and fluency; those

coronavirus disease 2 (SARS-CoV-2), may directly invade the brain.

older than 60 years old fared the worst16 whereas young, previ-

Both SARS-CoV-2 and SARS-CoV use human angiotensin-converting

ously healthy individuals recovered within 4 months after infection.41

enzyme 2 (ACE2)17

receptors as the molecular mechanism for invading

In a sample of COVID-19 patients discharged from critical care to

cells. These receptors are richly expressed in the brain and olfactory

rehabilitation, 80% had working memory, set-shifting, attention, and

bulb.18,19 It is reasonable then to consider whether SARS-CoV-2’s

processing speed deficits.42 In two independent studies of patients

effects on the olfactory bulb (resulting in anosmia) may extend into

discharged to home, clinically significant cognitive impairment per-

the olfactory cortical network.20–27 Experimental work in non-human

sisted in 60% to 70% of patients 3 to 4 months after discharge,

primates28 and rodents26 has provided evidence in support of this

with verbal learning, psychomotor speed, and executive function most

mechanism. Neuroimaging in sub-acute COVID-19 patients also pro-

affected.11,13 Finally, in two independent studies of patients assessed 6

vided evidence of regional involvement of the olfactory bulb and its

months after hospital admission for mild to moderate COVID-19, olfac-

first- and second-order projections.29–34 We note too that involve-

tory dysfunction and cognitive impairment were linearly predicted

ment of the olfactory cortical network in early Alzheimer’s disease (AD)

by older age but not disease severity.43,44 Thus, there is a connec-

is well established, and olfactory dysfunction is a strong clinical cor-

tion between COVID-19 and lingering cognitive impairment. The data

relate of mild cognitive impairment (MCI) in AD and other forms of

also suggest that even asymptomatic infections can result in cognitive

dementia.35–37

dysfunction.

Other possible (or additive) pathological mechanisms that may
underlie chronic neurological consequences of SARS-CoV-2 infection include persistent cytokine-mediated inflammation, antibody-

1.3

SARS-CoV-2 and the risk of early AD

mediated autoimmunity, and cerebrovascular pathology. These all
contribute to the acute neurological complications of COVID-19 and

The idea that infectious agents may contribute to the risk of AD was

may act as predisposing factors or ongoing insults for chronic or

recently reaffirmed.45–50 A meta-analysis of >100,000 participants

progressive neurological impairment.

found that several viruses associated with a higher risk of AD,51 and

Given these concerning findings, it behooves the scientific and medi-

bacteria have also been implicated.47,51 The presence of immunity

cal community to attempt to understand the molecular and/or systemic

to herpes simplex virus 1 (HSV-1), the best studied pathogen, corre-

factors linking COVID-19 to neurologic illness, both short and long

lates with greater cognitive impairment52 and increased neuropatho-

term. The following review describes what is known so far in terms

logical biomarkers of AD in humans.53,54 In mice models, HSV-1

of links among COVID-19, the brain, neurological symptoms, and AD

infection increases the expression of amyloid precursor protein,55 trig-

and related dementias (ADRD), with a focus on risk factors and pos-

gers the accumulation of amyloid beta (Aβ) and hyperphosphorylated

sible molecular, inflammatory, and viral pathways. We conclude with

tau,54,56,57 and impairs adult hippocampal neurogenesis.52 ,56–59

a description of the Alzheimer’s Association Consortium on Chronic

Of note, susceptibility to COVID-19 is driven in part by risk fac-

Neuropsychiatric Sequelae of SARS-CoV-2 infection (CNS SC2), which

tors that overlap with those of ADRD, including older age60,61 and

seeks to address these and other questions through an international

apolipoprotein E (APOE) ε4 status.62–64 In regard to the latter, in

consortium.

vitro experiments show that human neurons derived from induced
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pluripotent stem cells (iPSCs) are more susceptible to SARS-CoV-2
infection and neurodegenerative changes if they carry APOE ε4/ε4

1.5
Epidemiological factors predictive of
cognitive impairment

genotypes.65 Given that ethnic minorities in both the United States and
UK,66,67 as well as in individuals globally who have blood type A,67,68

Though sedentary lifestyle, smoking, and obesity (but not heavy alcohol

are at higher risk of COVID-19 complications and death, it appears

consumption) are related to increased rates of COVID-19 hospi-

that ancestry interacts (whether directly or through health disparities)

tal admissions,94 specific risks for transient or persistent cognitive

with environmental factors to contribute to SARS-CoV-2–related dis-

impairment after SARS-CoV-2 infection have not yet been identified.

ease susceptibility, and therefore potentially also COVID-19–related

Diabetes mellitus increases the risk for dementia and other severe out-

ADRD risk. In short, after the acute pandemic recedes, its sequelae are

comes after SARS-CoV-2 infection.40 Diabetes is highly prevalent in

likely to impact dementia research for years to come.1 The possibility

certain demographics, such as Blacks and Latinos, and these groups

that such sequelae may deepen existing health inequities heightens the

also appear to be at higher risk for the neurological complications of

need to focus future research on the long-term impact of SARS-CoV-2

COVID-19.95 Disparities in COVID-19 hospitalizations and mortality

infections on minoritized and unrepresented populations.

according to ethnicity remain even after correcting for neighborhood,
household crowding, smoking, body size, diabetes, and mental illness.96
Age also appears to be a factor, as COVID-19 patients who are

1.4

The complexity of AD causation

≥65 years of age have more severe systemic disease and higher rates
of neurologic complications. It is already well known that COVID-

The total number of people living with dementia worldwide approaches

19 morbidity and mortality are very high in the elderly population,

50 million and is projected to surpass 130 million by 2050,69 the major-

with 6 to 930 times higher likelihood of death compared to younger

ity of whom have AD. Despite massive investments, no effective treat-

cohorts. The highest risks are among the most elderly (≥85 years)

ments are available.70–73 Slow progress in understanding and treating

and older persons with medical comorbidities such as hypertension,

AD may be due in large part to disease heterogeneity and the mul-

diabetes, heart disease, and underlying respiratory illness.60 Elderly

tiplicity of causal

contributions.69,74

However, dementia syndromes

patients with preexisting neurologic diseases are both more suscepti-

continue to be refined with contributions from neuropathology, lon-

ble to severe COVID-19 infection and show higher rates of mortality

gitudinal clinical assessments, advanced neuroimaging, and molecu-

than their neurologically healthy counterparts.60,61 Most intriguingly,

lar markers.69,73,75 The emerging view is that dementias comprise

in a very large study of the UK Biobank, the APOE ε4/ε4 genotype was

overlapping phenotypes linked to multiple biological substrates.76,77

associated with COVID-19 test positivity at genome-wide significance

Studies of causation reveal contributions from genetic variations,

in individuals of European ancestry, and the APOE ε4/ε4 genotype was

lifestyle choices, and environmental risk factors, including infections,

also associated with a 4-fold increase in mortality after testing pos-

plus highlighted interactions among them.69,74,78,79

itive for COVID-19.33 This finding was replicated in an independent

Identification of causal genetic variation was expected to guide

community sample in Spain.64

development of disease-modifying treatments for dementia, yet at
the time of this submission, the majority of heritability remains unexplained despite large lists of disease-associated genetic variants.69
Risk prediction improves when large numbers of genetic variants

1.6
Clinical factors predictive of cognitive
impairment

are combined into polygenic risk scores (PRS), but these successes
are largely limited to populations of European ancestry.80–82 When

Variations in host immune responses to SARS-CoV-2 infection may

applied across ancestry groups, or even across different segments of

partially explain age and sex differences in disease severity,97,98 and

the same ancestry, PRS performance deteriorates.83 Therefore, the

possibly also the frequency and severity of chronic sequelae.1 Lev-

genetics of under-represented minorities in genetic studies of ADRD

els of inflammatory markers, such as C-reactive protein,99 ferritin,100

represent a severe knowledge gap that increasingly may result in

and D-dimer101 were associated with elevated risk of poor out-

greater health disparities as precision medicine becomes the prevalent

comes of COVID-19 in a dose-dependent manner, and a marker of

paradigm.84

heart failure was associated with increased mortality in COVID-19

It is our firm belief that untangling the complexity of ADRD will

pneumonia.102 Delirium in hospitalized COVID-19 patients also corre-

require novel, data-driven strategies that take advantage of complex

lates with elevated inflammatory markers.10 However, in community

datasets (neuropsychological, environmental, neuroimaging, genomics,

cases, COVID-induced impairments in short-term memory, attention,

blood-based biomarkers),85–87 deep learning and explanatory artificial

and concentration did not correlate with hospitalization, treatment,

intelligence,88 and the inclusion of ancestral populations89 to uncover

viremia, or acute inflammation.41 Likewise, in patients discharged from

naturally occurring data structures or architectures. Such an approach

critical care to rehabilitation, persistent executive dysfunction was not

is discovery based and agnostic, allowing diagnostic heterogeneity and

associated with mechanical ventilation or preexisting cardiovascular or

overlap to assist in the uncovering of specific biological mechanisms. A

metabolic disease.13 On the other hand, in a small sample of community

promising environmental factor that could be used in such an effort is

cases with mild symptoms, hyposmia was correlated with cogni-

SARS—CoV-2 exposure,18,20,28,90–93

tive impairment.103 Although younger patients (<60) may frequently
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complain of cognitive dysfunction, objective changes in performance

neurotoxicity of SARS-CoV-2 in human iPSC-derived neuron-astrocyte

are mild or absent in this group. The best predictors of subjective

co-cultures and brain organoids were found to be much higher in

cognitive impairment in younger adults include psychiatric complaints

APOE ε4/ε4 neurons and astrocytes.114 Systems biology approaches

and physical symptoms (headache, diarrhea), with the only common

have predicted the interaction between prohibitins, a class of mito-

risk factor across age groups being olfactory dysfunction.6,14,103,104

chondrial proteins, and SARS-CoV-2.115 The same prohibitins have

Taken together, these findings hint at a role for inflammation in dis-

been shown to mediate altered mitochondrial bioenergetics in olfac-

ease severity generally, but not necessarily for cognitive sequelae, and

tory bulb neurons donated from AD patients,116 possibly representing

reinforce concerns about olfactory involvement in relation to cognitive

a common underlying molecular mechanism. A broader picture of

impairment.

overlapping mechanisms in the olfactory bulb includes equivocal dis-

There are overlapping risk factors between COVID-19–induced

ruption of mitogen-activated protein kinase cascades, which has been

cognitive impairment and progressive cognitive decline and AD. Both

detected specifically in the olfactory bulb in AD116 and is a hall-

ADRD and COVID-19 are age-dependent disorders, becoming much

mark of SARS-CoV-2 infection.117 Furthermore, cases of persistent

more frequent and severe with advancing

age.47

Morbidity and mor-

anosmia and parosmia may in fact reveal pre-existing neurogenesis

tality of COVID-19 are also elevated in AD, and individuals with AD

defects, unmasked by SARS-CoV-2 infection and providing the niche

are more likely to develop COVID-19 and to die as a consequence of

for the onset of neurodegenerative disease.21 Along with neuropatho-

the

illness.47

Other risk factors potentially linking SARS-CoV-2 infec-

logical evidence of SARS-CoV-2’s intraneuronal entry, its neuroin-

tion with progressive cognitive decline and ADRD include molecular

vasive potential may be defined by immune fitness on the cellular

pathway abnormalities, clinical profiles, and partially overlapping neu-

level.

roimaging signatures. The ACE2 receptor acts as the ligand for the

Neuroimaging studies also provide possible links between COVID-

spike protein of SARS-CoV-2 mediating cell entry.105 ACE2 expres-

19 and brain changes. A defined profile of brain positron emission

sion declines with age, resulting in a pro-inflammatory state that

tomography hypometabolism in long COVID patients with biologically

may explain the increased severity and comorbid diabetic and hyper-

confirmed SARS-CoV-2 and persistent memory impairment was shown

adults.1

SARS-CoV-2 specif-

more than 3 weeks after the initial infection symptoms. Alterations

ically infects endothelial cells expressing ACE2, potentially leading

involved the olfactory gyrus and connected limbic/paralimbic regions,

to the observed deterioration of vascular architecture.1 This could

extending to the brainstem and cerebellum, and were associated with

lead to brain hypoperfusion and accelerate cognitive decline in the

symptoms.118 In older adults (average age 66), a significant reduc-

elderly.1,90,40 As a result of ACE2 downregulation, SARS-CoV-2 infec-

tion of frontoparietal and temporal glucose metabolism was related to

tion in older adults induces aggressive secretion of pro-inflammatory

cognitive impairment.8 These reductions persisted with some improve-

cytokines.1

Indeed, COVID-19 results in high levels of proinflamma-

ment 6 months after COVID-19 diagnosis.119 Conversely, in younger

tory cytokines, acute respiratory distress, and hypoxia, each of which

individuals, persistent impairment in executive function, attention, and

may contribute to cognitive decline in healthy and in already pre-

less frequently in memory are far more common in women and associ-

tensive complications observed in older

disposed

individuals.1,40,106,107

Pro-inflammatory cytokines increase

oxidative stress, resulting in downregulation of excitatory amino acid

ated with hypometabolism in the cingulate cortex, precuneus, and brain
stem.120,121,122

transporters and elevated glutamate levels, which may, in turn, cause

The reviewed literature does not, however, prove a link between

excitotoxicity. This pathway is already postulated to play a role in sev-

SARS-CoV-2 infection and ADRD. Most specifically, no available evi-

eral neurodegenerative diseases, including ADRD. The olfactory bulb

dence supports the notion that cognitive impairment after SARS-CoV-

has one of the highest levels of ACE2 expression in the brain, and direct

2 infection is a form of dementia (ADRD or otherwise), because no data

viral entry into neurons may create an additional cytotoxic insult.107

regarding the progression of neuropathological disease are available.

Even a transient presence of the virus in the olfactory bulb may

Even though COVID-19 has significant, attendant lethality in the acute

precipitate an underlying proteinopathy associated with age-related

phase, death is not a result of an extended, progressive neuropatho-

neurodegenerative disorders.1 ,108–111 The neuroinvasive potential of

logical disease. Therefore, until and unless a clear progressive pattern

SARS-CoV-2 may result in senescence of several different CNS cell

of disease is demonstrated in at least some individuals as a direct

types, including oligodendrocytes, astrocytes, and neural stem cells

sequela of infection with SARS-CoV-2, this will remain an open ques-

that can differentiate into neurons that integrate into the granule

tion. The longitudinal methodologies espoused by the consortium are

layer.1,112 Viral aggravation of underlying AD neuropathology has the

intended to provide data to answer it as clearly as possible controlling

potential to hasten the onset of, or further deteriorate, motor and

for possible confounders.

cognitive deficits.20,40,112
In silico network-based relationships have been reported as pathways and processes that are implicated in ADRD, and they have been
confirmed in transcription studies.113 In addition, abnormal expression of AD biomarkers was found in the cerebrospinal fluid and

1.7
The Alzheimer’s Association Consortium on
Chronic Neuropsychiatric Sequelae of SARS-CoV-2
infection (CNS SC2)

blood of patients with COVID-19.113 As already mentioned, APOE
ε4, a strong genetic risk factor for ADRD, has been associated with

Collectively, the information reviewed here provides important clues

increased risk for severe COVID-19. Notably, the neurotropism and

and evidence to support a hypothesis that cognitive impairment after
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SARS-CoV-2 infection in older adults may be progressive in nature and

2.2

Enrollment criteria

associated with epidemiological risk factors (including genetic ancestry), biomarkers, and neurosignatures that are overlapping with, or

New cohorts will recruit participants of age ≥50 years, with the cut-off

identical to, those of ADRD. To test this hypothesis, the Consortium

being different in some locations. About half of COVID-10 hospitalized

has embarked on a large-scale, international collaboration to provide

patients are >55 years, making them a good population for investi-

a harmonized set of tools and protocols to probe the association of

gating interactions between viral infections and the risk of cognitive

SARS-CoV-2 infection with neurological, psychiatric, and cognitive out-

decline and dementia.1,18 Both males and females will be recruited.

comes in a variety of settings covering ethnically and geographically

Existing cohorts will not include new recruitment for the purpose of

diverse populations. The underlying hypothesis is that the COVID-19

harmonization with the Consortium, but instead will collect a minimum

pandemic will increase rates of cognitive decline and dementia in older

harmonized data set (see below).

adults worldwide, presenting a very unwelcome but unique opportunity to understand interactions between the genomic risk of ADRD and
relevant environmental factors, including viral exposure to SARS-CoV-

2.3

Recruitment and sampling procedures

2.18,20,90–93,123 The primary objective of this large-scale collaboration
is to clarify the pathogenesis of ADRD and to advance our under-

The principal objective of the CNS-SC2 protocol is to provide suffi-

standing of the impact of a neurotropic virus on the long-term risk of

cient flexibility of recruitment methods and data collection to member

cognitive decline and other CNS sequelae. The proposed harmoniza-

countries to maximize sampling opportunities, while at the same

tion strategies and flexible study designs offer the possibility to include

time harmonizing procedures and methods sufficiently to allow for

large samples of under-represented racial and ethnic groups, creating

cross-site comparisons, meta-analytic approaches, and other forms of

a rich set of harmonized cohorts for future studies of the pathophysi-

appropriate data collation. Thus, participant recruitment processes are

ology, determinants, long-term consequences, and trends in cognitive

permitted to vary as described below, depending on the site and study

aging, ADRD, and vascular disease. Thus, the present proposal pro-

sample. Screening questionnaires will be used to determine eligibility

vides a framework for current and future studies to be carried out

and recruit participants via either telephonic and video interviews or

within the Consortium. and offers a “green paper” to the research com-

during clinic and hospital visits. When possible, one informant (family

munity with a very broad, global base of support, on tools suitable

member or close friend) will be enrolled per participant. A description

for low- and middle-income countries aimed to compare and com-

of ongoing recruitment efforts is provided in Table 1. We plan to use

bine future longitudinal data on the topic. Our specific hypothesis is that

several complementary recruitment frameworks:

SARS-CoV-2 triggers ADRD-like pathology following the extended olfactory
cortical network (EOCN) in older individuals with specific genetic suscepti-

1. Hospital-based samples: We propose to derive these from sam-

bility. Of specific interest is the consequence that cognitive complaints

pling frames constructed using current lists of hospital admissions

in younger adult individuals may be of a different nature than those

for COVID-19 in academic centers. Participating academic groups

observed in older adults and obey different molecular mechanisms,

with immediate access to hospital admissions data for patients

clinical course, and outcomes. The proposed methods will allow us to

who tested positive for COVID-19 allow recruitment of persons

address this and other questions.

at relatively high risk of neurological complications, given that
severity of infection warranted hospitalization. That is, while the
relationship between acute severity and neurological complications

2

METHODS

does not hold as well for individuals with less severe disease, it
is well established for cases that required hospitalization.5 Such

2.1

Enrollment countries

patients will be contacted and offered enrollment in a cohort with
a minimal longitudinal follow-up of between 12 and 24 months of

Member countries include (see Figure 1): Argentina, Australia, Aus-

the initial assessment. Representativeness of the sample will be

tria, Bolivia, Brazil, Canada, Chile, China, Colombia, Cuba, Denmark,

determined by comparing characteristics of the full list of hospital

Dominican Republic, Ethiopia, Finland, France, Germany, Greece, Haiti,

admissions against those who enroll. Wherever possible, individ-

Honduras, Iceland, India, Israel, Kenya, Mexico, the Netherlands, Nige-

uals discharged from the hospital but negative for COVID-19

ria, Peru, the Philippines, Qatar, South Africa, Spain, Sweden, Tanzania,

infection (and matched for age range) will be recruited to repre-

Thailand, Uganda and the UK (England, Wales, and Scotland). Given the

sent the background risk of cognitive decline and neuropsychiatric

variety of countries involved, cohorts will allow inclusion of all major

pathology and act as a control group. For instance, the ongoing

genetic backgrounds found in low, lower–middle, upper–middle, and

recruitment in Greece uses patients with chronic obstructive pul-

high-income countries. Data collection is already ongoing using com-

monary disease admitted with complications as the comparison

ponents of the presented methodology in Argentina, Canada, Greece,

group. Further, there are extended comparison groups at some

India, Israel, and the United States and will commence soon in several

sites, such as a cohort of Early Onset Alzheimer’s Disease with deep

other of the member countries.

clinical and biogenetic phenotyping in England (NCT04992975;
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FIGURE 1

Map of countries of origin of Consortium members

NCT03861884). Most ongoing data collection (for instance in

SC2. COVID-19 status will be determined using both standardized

Canada, Greece, England, South Africa, and in San Antonio, Texas,

case report forms (CRFs) developed by the NeuroCOVID Forum

USA) follow this model.

of the World Health Organization (WHO) and via antibody titer

2. Population registry samples: Wherever they are available, we will

for SARS-CoV-2 exposure. Participants in these cohorts already

establish new cohorts by sampling from existing national, regional,

have pre-existing extensive baseline phenotyping, and in many

or local (e.g., city) population registries that include SARS-CoV-2

cases have been extensively genotyped as well, allowing direct

testing data (regardless of hospitalization or the result of the test-

assessment of predictors of the short- and long-term effects of

ing) as part of the pandemic response. Such samples will include a

exposure to COVID-19 infection and complications from SARS-

wide range of acute COVID-19 outcomes, including respiratory or

CoV-2. Because follow-up data collection in surviving participants

general symptoms severe enough to warrant hospitalization (with

of such historic samples are less likely to be representative of

and without intensive care admission), mild symptoms (managed in

the original populations they were sampled from, analyses will

ambulatory settings), asymptomatic positive individuals, and those

check for lost to follow-up (non-participation) bias. However, as

who tested negative. The latter will act as controls for infected

with comparisons with pre-COVID-19 samples (below) that are

participants. From these lists, we will randomly invite participants

unlikely to have adopted the same measurement methods used in

stratified by testing status and regardless of symptom severity. This

this protocol, synthetic data analysis methods will be required to

approach will make it possible to estimate population-level effect

combine findings from newly enrolled samples (e.g., recruitment

sizes, including error estimates that take account of, and are cor-

frameworks 1 and 2 above). In this case, cohort participants who

rected for, each sampling fraction and the numbers successfully

remained free of infection during the pandemic will act as ideal

obtained, leading to greater external validity. Cohorts collected

controls, because they have extensive pre-pandemic phenotyping.

with this methodology are being recruited in Argentina and the

Pre-existing cohorts of these characteristics are available in, for

United States (Laredo, Texas). To trim the samples, scores from

instance, Australia, Denmark, England, India, and New York City in

semi-structured interviews may be used to determine the clinical
severity of the COVID-19 and to populate the stratified sample
from the cohort.

the United States, among several others.
4. Population-based pre and post COVID-19 multiple, crosssectionally representative (probabilistic) samples: Where available,

3. Pre-existing population-based cohort samples of aging individuals:

these may also be included to compare pre and post COVID-19

Wherever there are surviving participants of ongoing, longitudi-

individuals. Such designs provide extensive pre COVID-19 popu-

nal, community-based cohort studies already collecting biosamples,

lation data for comparison with a new sample to be collected post

and cognitive, behavioral, and neuroimaging data in populations

COVID-19 in the same individuals. Whereas participant data in the

that fit our age criteria, we will attempt to include them in CNS-

pre COVID-19 samples can be presumed to be COVID-19 negative,
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TA B L E 1

Current active cohorts in the Consortium

Argentina

Ministry of Health – Jujuy

Dr. Agustin Yecora

ISAVRAD

865

Australia

Centre for Healthy Brain Ageing
(CHeBA) – University of New South
Wales

Dr. Katya Numbers

MAS

173

Australia

Centre for Healthy Ageing

Prof. Hamid Sohrabi

Western Australia Memory
Study

Projectd: 200

Cuba

Universidad de Ciencias Medicas de la
Habana

Prof. Antonio Caballero

Longitudinal study of
convalescent COVID-19
patients

∼400

France

Clinique de la Mémoire. Université de
Paris

Prof. Jacques Hugon

Longitudinal follow up
post-COVID-19 with PET
imaging

100

Greece

University of Thessaly

Dr. George Vavougios,
Prof. Konstantinos I.
Gourgoulianis

COVALENT Tier 1 and Tier
2 Cohorts

250 and 200,
respectively

India

Iqra International Hospital and
Research Center – Calicut, India

Dr. Uvais Arakkal

CNS SARS CoV-2:
Prospective Cohort

Pilot initiated

India

Center for Brain Research, IISc –
Bangalore, India

Dr. Vijay Ravindranath,
Jonas Sundarakumar

SANSCOG and TLSA
studies

3170 and 583,
respectively

Israel

University of Haifa

Dr. Galit Weinstein

Pilot initiated
Collaborative study

∼200

South Africa

University of Cape Town

Prof. Dan Stein

UK

University of Leicester

Dr. Elizabetta
Mukaetova-Ladinska

UK

University of Nottingham

Dr. Akram Hosseini

7T MRI COVID Project

USA

University of Mississippi

Prof. Thomas Mosley

Member of ARIC

5046

USA

Pacific Neuroscience Institute

Dr. David Merrill, Dr.
Stella Panos

Pacific Brain Health Center
Clinic

Pilot initiated

USA

UT Health San Antonio, University of
Pittsburgh, Houston Methodist,
Massachusetts General Hospital

Drs. Sudha Seshadri,
Gabriel de Erausquin

7T MRI COVID Project

≈240

USA

UT Health San Antonio/Laredo

Drs. Sudha Seshadri,
Gabriel de Erausquin

ISAVRAD

250

USA

Albert Einstein Medical College

Mindy Katz

Bronx Study of Aging

250

Venezuela

University of Zulia, University of Texas
Rio Grande Valley

Drs. Gladys Maestre,
Carlos A. Chavez

Maracaibo Aging Study

Pilot initiated

Abbreviations: ARIC, Atherosclerosis Risk in Communities; COVALENT, A COVID-19 Clinical, Research and Phenotyping Network; COVID, coronavirus disease; ISAVRAD, Interaction between SARS-CoV-2 Infection and Ancestral genomic Variations in the Risk of Alzheimer’s Disease and Related Disorders; MAS,
Memory and Aging Studies; MRI, magnetic resonance imaging; PET, positron emission tomography; SANSCOG, Srinivaspura Aging, Neuro Senescence and
Cognition; TLSA, Tata Longitudinal Study on Aging; UT, University of Texas.

it will be necessary in the post COVID-19 samples to determine

cohorts will be a positive result on either a polymerase chain reac-

their case status by questionnaire or COVID-19 test results. Such a

tion (PCR) test or, where available, a positive antigen test at the time

design will be able to disaggregate the effect of viral infection from

of detection. A positive PCR occurring within 3 months of enrollment

the social, economic, and psychological effects of living through the

will be exclusionary, as it could indicate current infection. Because

pandemic period. Samples obtained with this methodology will be

the pandemic is still ongoing, seroconversion of participants in the

available in England and Pakistan.

uninfected comparison group is a potentially serious concern. Seroconversion could occur after the documented initial negative PCR but
before the initial assessment or after the initial assessment but prior

2.4

Identification of SARS-CoV-2 exposure

to the 24-month follow-up visit. The primary method for confirming seronegativity will be lack of detection of circulating antibodies

COVID-19 positivity will be categorized as definite, probable, and

against SARS-CoV-2 nucleocapside protein.124 We will also strive to

possible based on testing, documentation, and symptomatology (see

collect clinical history documentation and monitoring of the registry

Table 2). However, the only criterion for inclusion in prospective

for repeated PCR tests documenting active infection at a later time.
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TA B L E 2

Case definitions

presented and discussed at several stages of development to the WHO
Work Group, whose members have provided feedback and techni-

Definite case definition variants

cal advice. The WHO CRF will be used to stratify COVID-19 severity

Positive infection test (PCR or rapid test)
Positive infection test with a later positive antibody test
Positive infection test with at least 2 core symptomsa

according to a four-level scale: Care level 0: no treatment required;
Care level 1: ambulatory treatment; Care level 2: hospital admission
without or with oxygen supplementation; and Care level 3: intensive

Positive infection test with at least 1 core symptom ˆ and 2
supportive symptomsb
Positive infection test, core symptoms, and hospitalization as an
index of severity

care unit admission with or without mechanical ventilation.

2.6

Data collection time points

Probable case definition variants
Antibody test positive on two occasions (without vaccination)
Positive antibody test (without vaccination) with at least 2 core
symptomsa or 1 core + 2 supportive symptoms
a

Negative infection test with at least 2 core symptoms or 1 core
+ 2 supportive symptoms and typical chest CT

The minimum expectation calls for three data points (i.e., baseline and
12 and 24 months). A schematic description of the planned data collection is provided in Figure 2. Because cohorts such as those proposed
here are highly valuable assets, longer follow-up is desirable and will be
sought.

Possible case definitions (e.g., drawn from survey
questionnaires or interview findings)
Single core symptoms

2.7

Core outcome measures (minimum data set)

Self-reported without laboratory testing confirmation
Positive antibody test on just one occasion (without vaccination)

Since the first cases of human infection by SARS-CoV-2 were detected
just over 2 years ago, it is impossible to predict the range of neu-

a

Core symptoms: fever, chills, cough, sore throat, anosmia, dyspnea,
hypoxia, muscle pain, fatigue, altered mental status, or delirium.
b
Supportive symptoms: diarrhea, headache, skin rash.
Abbreviations: CT, computed tomography; PCR, polymerase chain reaction.

ropsychiatric sequelae that may ensue. On the other hand, as reviewed
above, acute and post-acute manifestations of COVID-19 disease
commonly include cognitive impairment, and less frequently, overt psychiatric symptoms including mood abnormalities and psychosis. There-

Even with careful monitoring of both, we may fail to identify asymptomatic infections in some individuals. However, this limitation may
improve the robustness of any findings of cognitive decline in the
targeted population (i.e., participants with documented positive infection), because undetected asymptomatic infections would have the
effect of increasing cognitive decline in the comparison group, reducing
any potential group differences.

2.5

Stratification of COVID-19 symptom severity

fore, we have chosen assessment instruments that allow an exhaustive
assessment of neurological and psychiatric symptoms. Given the multinational nature of the consortium, we have also chosen instruments
that are available and validated in as many languages as possible or, as
is the case for cognitive assessment tests, are as unbiased as possible
when used in individuals with varying mother tongues, literacy levels,
and cultural contexts. The following specific tools were selected (see
Table 3):
1. Phenomenological description: To be able to capture novel patient
descriptions and clinical signs, our assessment approach is flex-

For symptom severity, baseline evaluations of all enrollees will include

ible and semi-structured. Specifically, the WHO semi-structured

(as part of the minimum data set for all cohorts) detailed CRFs for

interview Schedules for Clinical Assessment in Neuropsychiatry

COVID-19 developed by the WHO’s NeuroCOVID-19 Work Group

(WHO SCAN) will be used to ascertain psychopathology and neu-

(several Consortium investigators including the lead author are mem-

rological symptoms.125 Version 3 of WHO SCAN contains detailed

bers of this group). The protocol proposed in this article has been

semiquantitative (dimensional) assessments of the subject’s report

F I G U R E 2 Proposed longitudinal schedule for assessment of cohort members. FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging;
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
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Summary of data to be collected

Domain

Measures

Clinical, cognitive, and psychosocial assessments
Cognitive domains

Orientation & language*

ACE III and Shortened Boston Naming Test

Memory

Episodic: Visual Paired Associates
Working: Corsi Block-Tapping Test
Semantic: Cactus & Camel Test

Executive function

Inhibition (& psycho-motor speed): Color (or Size) Stroop
Planning – Problem solving: Tower of Hanoi
Decision making – Impulsivity: Iowa, Gambling task

Psychomotor speed

Symbol Substitution Test

Attention & visuo-spatial abilities

Search Neglect: Bell cancellation
Perception Apperceptive Agnosia: Poppelreuter-Ghent’s
Overlapping Figures Test

Social cognition

Theory of Mind: Frith-Happé animations

Neuropsychiatry and behavioral
neurology

World Health Organization Schedules for Clinical Assessment in Neuropsychiatry (WHO SCAN)

Clinical evaluation of
neurodegenerative disorders

The National Alzheimer’s Coordinating Center Uniform Dataset (NACC UDS)

Emotional reactivity assessment

The Perth Emotional Reactivity Scale (PERS)81

Clinical cognitive diagnosis

Mild cognitive impairment (amnestic or non-amnestic), and dementia

Psychosocial measures

Quality of life measures; stressful life events; poverty and financial hardship

Semiquantitative clinical variables

Anosmia/hyposmia smell recognition test; 2-minute walk test of fatigability

Neuroimaging
Structural MRI

Region specific volumetric, cortical surface White matter hyperintensities as a proxy for vascular disease
Vascular lesion burden: Infarcts, microbleeds

Diffusion tensor imaging

Tract-specific fractional anisotropy (FA) and mean diffusivity (MA)

BOLD fMRI

Data from functional connectivity (FC) analyses BOLD-derived voxel-based physiological (VBP) indices
of neurovascular coupling

18

Region-specific glucose uptake as markers of tissue metabolism and synaptic integrity

F-DG PET (only at UTHSA site)

Blood-based biomarkers
AD-specific biomarkers

Aβ42, Aβ40, p-tau181 , p-tau217

Neurodegeneration and neuronal
activity/injury

NfL, GFAP, sTREM-2

Inflammatory biomarkers

Bio-Plex Pro Human Cytokine panel: FGF basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-1α,
IL-2Rα, IL-3, IL-12 (p40), IL-16, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, GRO-α, HGF, IFN-α2, LIF, MCP-3,
IL-10, IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, MCP-1 (MCAF), MIG. β-NGF, SCF, SCGF-β, SDF-1α,
MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF, CTACK, MIF, TRAIL, IL-18, M-CSF, TNF-β

Genetics
DNA collection for GWAS or Whole Genome Sequencing
Note: Harmonized measures will not be able to be collected as suggested at all sites. The intent of the list of measures is to secure harmonization of those
measures that are locally available, to ensure maximum and optimum data shareability.
Abbreviations: Aβ, amyloid beta; ACE III, Addenbrooke’s Cognitive Examination III; AD, Alzheimer’s disease; BOLD, blood oxygen level dependent; 18 F-DG;
fluorodeoxyglucose; fMRI, functional magnetic resonance imaging; GFAP, glial fibrillary acidic protein; GWAS, genome-wide association studies; MRI, magnetic resonance imaging; NfL, neurofilament light chain; PET, positron emission tomography; p-tau, phosphorylated tau; sTREM-2, soluble triggering receptor
expressed on myeloid cells 2; UTHSA, University of Texas Health San Antonio.
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of behavioral neurology (cognitive efficiency, memory for recent

literacy; and (3) reasonably brief (it takes less than 60 minutes to

events, executive function, language, etc.), and psychiatry (anxi-

complete). Details are provided in Table 3. The neuropsychiatric

ety, mood, hallucinations, delusions) phenomenology, as well as the

manifestations of SARS-CoV-2 infection have been characterized

interviewer’s observations of interviewee behaviors. WHO SCAN

in the acute phase of the disease, but less is known about long-term

also provides automatized algorithms for all of the clinical diagnosis

sequelae. Given this uncertainty, it is reasonable to include tests

contained in Section F of the International Classification of Dis-

that probe multiple cognitive domains. Because both cortical and

eases revisions 10 (ICD-10) and 11 (ICD-11). When possible, and

subcortical circuits may be affected, a broad cognitive assessment

as provided for in WHO SCAN, informants will be interviewed for

is warranted. Pictorial versions of most tests are proposed to

their impressions of the subject’s cognition and to confirm the accu-

minimize biases imposed by language of origin and literacy levels.

racy of the subject’s responses. Pre COVID-19 data on historical

The two tests that may need to be completed in a face-to-face

clinical phenomena and the previous life course, both of which are

format, as they require understanding of natural language, are the

important in modeling future outcomes, are also assessed in SCAN

Addenbrooke’s Cognitive Examination III (a short but comprehen-

and the SCAN 2.1 Clinical History Schedule, which takes account of

sive cognitive battery), and the shortened Boston Naming Test. All

externally provided data.

the other tests can be computerized easily. To our knowledge, there

With the exception of personality disorders, the WHO SCAN

is currently no Visual Paired Associates Test that clearly mirrors

covers all forms of neuropsychiatric outcomes, including somatic

the verbal version. Orbito-frontal functions will be assessed using

complaints; anxiety and mood disorders; obsessional phenomena;

the Iowa Gambling Task and the Probabilistic Reversal Learning

neurodevelopmental phenomena (autism, attention deficit hyper-

Task. The classic test for psycho-motor speed is the Digit Symbol

activity disorder); psychosis; drug, alcohol, gambling, and eating

Substitution Test. The battery is completed by test for neglect,

problems; and an assessment of cognitive decline. Outputs include

high order visual perception, and social cognition. We expect some

pre-specified symptoms (e.g., delusion, panic, elation), dimensional

degree of variation across sites on the specific tests used as a

symptom scores, and the determination of published diagnostic cri-

consequence of, among other things, the availability of local norms

teria. Experienced psychopathologists can be trained by means of

and validation, but every site will collect data on the same cognitive

a 3-day online course that includes role play and interview rat-

domains using analogous tests when the exact versions are not

ing sessions to ensure concordance and reliability. WHO SCAN

available. For meta-analytic assessments, we will use normalized

is coordinated by a WHO advisory group that can advise on

z-scores of the performance for each domain.

training, translation, and research protocol specifications with the
support of centers throughout the world. If WHO SCAN is not

The following supplemental measures are proposed to facilitate

available in the local language, the semi-structured interview for

comparisons and data collation across studies affiliated with the

the Clinical Dementia Rating (CDR) scale and the WHO Mental

consortium.

Health Gap Action Programme interview may be used as suitable
replacements.120

1. To facilitate data sharing with ongoing studies, wherever feasible

2. Neurological examination: The neurological evaluation at each site

sites will collect information to fill the National Alzheimer’s Coor-

is conducted and supervised by trained clinicians who are blind

dinating Center Uniform Data Set (NACC UDS).127–130 The NACC

to neuropsychological tests and PCR results and to SARS-CoV-2

established the UDS for longitudinal data by means of a standard-

testing status and history. The evaluation includes semiquantita-

ized clinical evaluation.127–130 NACC is responsible for developing

tive assessments of smell, visual, and auditory perception; muscle

and maintaining a database of participant information collected

strength and tone; eye and facial movements; coordination, gait,

from all of the Alzheimer’s Disease Centers (ADCs) funded by the

and balance; and muscular fatigue (after 2 minutes of walking).

National Institute on Aging (NIA). UDS defines an expanded, stan-

With participant consent, neurological exams will be videotaped.

dardized clinical data set to provide ADC researchers a standard

Diagnoses of parkinsonism and focality due to completed stroke

set of assessment procedures, collected longitudinally, to better

will be noted, as will incidental diagnoses of non-cognitive neu-

characterize ADC participants with mild AD and MCI compared

rological disorders (e.g., seizure neuropathy, headache). Finally,

to non-demented controls. The UDS has data collection forms for

the WHO SCAN interview permits the collection of the infor-

initial and follow-up visits based on NACC definitions, a relational

mation needed to score the CDR126 and will be used for this

database, and a data submission system enhanced to provide effi-

purpose.

cient and secure access data submission and retrieval systems

3. Cognitive assessment battery: A customized neurocognitive

(https://www.alz.washington.edu).128 The NACC UDS is validated

assessment was developed by a subcommittee of the Consortium

for international AD cohorts and is available in English, Spanish,

members with technical expertise and extensive representation of

and Chinese (Mandarin). Psychosocial measures, including quality

low- and middle-income countries (Argentina, China, Haiti, India)

of life, stressful life events, and poverty and financial hardship will

to meet three criteria: (1) adapted to multiple cultural settings and

also be collected where possible. Admittedly, this information is

languages, and therefore minimally biased by formal education

partially duplicative with other components of the proposed assess-

and native tongue; (2) robust to low levels of formal education or

ment. Local decisions over use will be driven by the availability of
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locally validated and culturally adapted assessment tools, as well as

with identical 7T MRI images include age-, sex-, and ethnicity-

participant burden.

matched participants who are both healthy or have an illness of

2. Emotional reactivity assessment: The Perth Emotional Reactivity

similar severity (intensive care unit [ICU] admission, hospitaliza-

Scale (PERS), a self-report measure of trait levels of emotional reac-

tion without ICU, or no hospitalization). The study of 7T imaging

tivity, assesses the typical ease of activation, intensity, and duration

precursors of AD will further benefit from an independent 7T

of individual positive and negative emotional responses.127 Con-

MRI study of patients with early onset AD as an additional com-

current validity has been demonstrated via congruent correlations

parison group (clinicaltrials.org Identifier: NCT04992975). We

with other emotion measures.131

will analyze the acquired data through data sharing agreements

3. Neuroimaging will be performed with two types of scans.
a. 1.5 and 3 Tesla scanners: To promote consistency in data anal-

based on the local expertise of each site within the 7T MRI
COVID Consortium.

ysis, we will follow standardized magnetic resonance imaging

4. Biomarkers: Collection methods for whole bloods, plasma, serum,

(MRI) imaging datasets developed for the acquired 1.5T and 3T

anucleated blood cells, mouth swab for epigenomics, and cere-

scans by the Alzheimer’s Disease Neuroimaging Initiative Study

brospinal fluid are detailed in Tables S1 and S2 in supporting

3 (ADNI-3). We are using ADNI phantoms to ensure adequate

information. Blood spot is recommended for all sites, and blood or

harmonization of data collection across sites. By so doing, we

salivary swab is recommended for DNA (genome-wide association

will optimize direct comparisons of various analysis methods,

studies). Participating sites will collect, store, use, share, and

particularly given large variations among older MRI systems

dispose of human biospecimens in accordance with the informed

and the state-of-the-art systems available at high-end academic

consent signed by the subject, or under a waiver of informed

centers. ADNI-3 provides a two-tiered approach to accom-

consent granted by an independent ethical review body at each

modate the range of variability in scanners, including ADNI-3

institution. When specimens are collected from humans for the

Basic and ADNI-3 Advanced. The latter include structural T1-

study purposes, the collection and storage process should aim

weighted, 3D fluid-attenuated inversion recovery, T2* gradient

to adhere, as closely as possible, to harmonized study protocols

recalled echo, arterial spin labeling, and high-resolution images

and procedures appropriate for the type of biospecimen being

of the hippocampus. The advanced diffusion MRI and rest-

collected and its intended uses. We will establish biorepositories

ing state functional MRI scans take advantage of simultaneous

within global regions where biospecimens will be collected. Raw

multi-slice acceleration for echo-planar images. For longitu-

data will be analyzed locally, such that only metadata will be shared

dinal consistency, advanced sequences can be downsampled

across the consortium. Specific agreements between each reposi-

post-scan to match the basic sequences. The standard ADNI-

tory and collection site will be (or have already been) established.

3 sequence acquisitions are listed in Table 3. We will collect

All biorepositories, whether large or represented by individual

region-specific volumetric and cortical surface measures; white

freezers in laboratories, will follow best practices using effective

matter hyperintensities as a proxy for vascular disease; vascular

facility environments that include ambient temperature controls,

lesion burden (including infarcts and microbleeds); tract-specific

good air circulation, lighting, and security. Systems will be in place

fractional anisotropy and mean diffusivity; BOLD-derived voxel-

to allow for local and remote temperature monitoring of freezers,

based physiological indices of neurovascular coupling; and, if

refrigerators, and other temperature-controlled environments.

PET is available, region-specific glucose uptake as markers of

Biorepositories will have emergency preparedness plans that cover

tissue metabolism and synaptic integrity.

equipment failures and power interruption that include back-up

b. 7 Tesla ultrahigh field scanners: The higher contrast and spa-

storage capacity and back-up power supplies such as genera-

tial resolution of 7T MRI provides submillimeter measurements,

tors

allowing study of small cortical and subcortical structures of the

documents/ethical_conduct/guidelines-biospecimen.pdf). Special

brain and providing superior detail to 3T. Enhanced anatomical

attention will be paid to the appropriate packaging and shipping of

detail at 7T allows higher sensitivity in measuring sub-structural

human biospecimens between the collection site and the biorepos-

volume loss, including hippocampal subfields132 and the earlier

itory. This includes conforming to all applicable regulations and

detection of neurodegeneration implicated in ADRD. The UK

standards, including, but not limited to, those of the US Department

7T Network (which includes members of the CNS SARS-CoV-2

of Transportation (DOT; DOT PHMSA PHH50-0079, 2006) and

consortium) have previously tested and proved the repro-

the International Air Transport Association (IATA; IATA Dangerous

ducibility of 7T scanners (Siemens and Phillips) across various

Goods Regulations, 2019; IATA Infectious Substances Shipping

sites.133–135 The harmonized sequences, listed in Table 4, are

Guidelines, 2019). All personnel involved in shipping biological

designed to study volumetric assessment of: cortex, hippocam-

materials should be trained properly for both air and ground

pal subfields, and thalamus; quantitative cerebral white matter

shipments. A full list of the proposed biomarkers is included in

changes and inflammation; iron content from blood breakdown

(https://oir.nih.gov/sites/default/files/uploads/sourcebook/

Table 3.

(cerebral microbleeds, microthrombi); markers of endothelial

5. Genotyping: Specific approaches will vary across sites, but at a

injury; and volume and injury to the sub-structures of the brain

minimum, each dataset will contain genome-wide genotypes from

stem, including locus coeruleus. Comparative control groups

cohort individuals to address the role of ancestry and genetic
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TA B L E 4

Description of 7 Tesla high field MRI sequences proposed

Sequence

Acquisition parameters

Measures assessed

Set up / localizer

GRE

Positioning; shimming

Time (min)

3DT1 MP2RAGE

348 slices (0.55 iso); TR∼6000; TE∼22.54;
TI1/2∼800/2500; AF=2

Morphometry; registration; hippocampus
segmentation

12.5

3D SWI

208 slices (0.375x0.375x0.75); TR∼24;
TE1/2∼8.16/18.35; AF=2

Small vessel analysis; T2* mapping; QSM

9

T2 TSE

36 slices (0.375x0.375x1.5); TR∼10060;
TE∼61; AF = 2

Hippocampus segmentation

4

T2 FLAIR

80 slices (0.75x0.75x1.5); TR∼14000; TE∼99;
TI∼2900; AF = 2

White matter hyperintensities

3D T2 Space

256 slices (0.6 iso); TR∼3400; TE∼367; AF = 3

Morphometry; hippocampus
segmentation; perivascular spaces

9.5

MT & non MT

60 slices (0.4 iso); TR=548; TE=4.08; AF = 8

Locus coeruleus intensity; contrast’ MT

8

TOF (4 slabs)

192 slices (0.375 iso); TR∼14; TE∼4.5; AF = 3

Angiography; arteriolar analysis

6.5

5.5

11

Abbreviations: FLAIR, fluid-attenuated inversion recovery; GRE, gradient echo; MT, magnetization transfer; MP2RAGE, magnetization-prepared 2 rapid
acquisition gradient echo; QSM, quantitative susceptibility mapping; SWI, susceptibility weighted imaging; TE, echo time; TOF, time of flight; TR, repetition
time; TSE, turbo spin echo.

variation on susceptibility to neuropsychiatric sequelae. When

reporting of viral genomes to the Global Initiative on Sharing All

available, sites will obtain whole-genome sequencing data. Our con-

Influenza Data (GISAID) website is the primary source for phylodynam-

sortium is in a unique position to address the interaction between

ics of SARS-CoV-2 in participant countries (https://www.gisaid.org/

genetics (including ancestral DNA) and viral strain variation on CNS

phylodynamics/) including most of the Consortium members. Because

sequelae of SARS-CoV-2. If available, genotyping will be carried out

individual-level data of viral genomes are unlikely to be available for

using Illumina GSA (or equivalent chip) and imputation to the best

most sites, prevailing variants at the time of infection for cohort par-

available panel for persons of specified ancestry.

ticipants will be used as a covariate for all analyses and meta-analyses.
Similarly, type and dose number of vaccines will be used as a covariate.
Another possible source of heterogeneity is the precision of COVID-19

2.8

Data analysis

diagnosis across sites, particularly when comparing academic centers
in developed countries to community samples in developing coun-

Longitudinal data analysis approaches, including generalized linear

tries. We will minimize the impact of such differences by adhering

models, will be used, depending on the outcome of our interests and

to WHO diagnostic criteria across the board, and by using the CRF

data distribution. Time-to-event models will also be considered if there

developed by the WHO workgroup on NeuroCOVID to collect clinical

are a sufficient number of data points. There will also be ample scope

information.

for nested case-control design approaches to analyze within selected

Data heterogeneity is an inescapable aspect of large-scale, multina-

subsets of the cohort data. These could be led by individual investi-

tional studies, but previous experience shows that it can be addressed

gators, for example, in small substudies for which limited numbers of

with appropriate harmonization.136–139 The Consortium has addition-

patients have undergone particular laboratory tests. When estimat-

ally adopted flexibility of study designs, which will increase the richness

ing the size of effects at the population level, and in particular for

of the datasets but further increase variability. The intent of the

probabilistic cohorts, error estimates will take account of and be cor-

Consortium members is that by harmonizing data collection and mea-

rected for each sampling fraction, leading to greater generalizability

surements we will increase the likelihood of cross-comparisons and the

and external validity. Where individual level data sharing is not possi-

interpretability of meta-analytic approaches. Neuropsychiatric seque-

ble, we will use meta-analytic approaches to compare findings across

lae of COVID-19 obey multifactorial causation and may potentially

countries.

emerge by the interactions of multiple, rather than a singular factor,

Despite the great effort made by the Consortium to harmonize

including baseline lifestyle differences, impact of social restrictions and

methods and assessment tools, the approach proposed here has lim-

other measures, type and timing of COVID-19 treatment (including

itations due to the likely heterogeneity of the samples that will be

vaccines), genomic viral variants, and possibly others. Observational

collected across several important dimensions. Ethnic and genetic het-

studies combining an in-depth analytical design and multiple measure-

erogeneity is a desirable feature of the approach and will increase

ments have been proposed as a means to address such a complex

generalizability of the findings across populations. On the other hand,

interaction problem.140 Also, integrative analytical approaches have

multiplicity of virus variants as the pandemic has progressed is a

been shown to perform well in observational studies in infectious

likely source of variance that will need to be addressed. Voluntary

diseases.141 Furthermore, more extensive measurements may more
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accurately capture and parametrize the biological question at hand, as

cally used in the United States (e.g., the National Adult Reading Test

has been shown by, for example, the inclusion of genetic data in obser-

or the Weschler vocabulary subtest) are very limited in high illiteracy

vational studies toward establishing inference.142 Causality inference

contexts such as Argentina. Most cognitive tests have robust norms

can be approached in a stepwise, tiered fashion that will be possi-

established in our study population. In making diagnoses, we will incor-

ble by the scope of the Consortium. For instance, estimands of causal

porate clinical judgment of cognitive decline, particularly with respect

relationships identified among recorded variables may be identified

to pre-morbid and baseline levels of cognition. Local norms that include

from prospective evaluation of COVID-19 survivors and the refine-

age and education will also be routinely considered, both in making

ment of associations.143 Confounders and mimics will be addressed

consensus diagnoses and in formal statistical analysis.

where possible via supplementary assessments where available (such
as psychosocial measures, including quality of life, stressful life events,
poverty, and financial hardship). Biomarkers and neuroimaging indices

2.11

Mortality endpoints

may also be used to improve causal associations.
In summary, the Consortium proposes a combination of design and

Efforts will be made to ascertain death certificates, contact significant

statistical methods as a means of approaching causal inference144,145

others, or to search the National Death Index (https://www.cdc.gov/

of the COVID-19 neuropsychiatric sequelae. We expect that deep

nchs/ndi/index.htm) to track participants who are lost to follow-up. In

phenotyping of neuropsychiatric sequelae may provide a series of

Argentina, we will track deaths in the registry of the provincial Emer-

candidate syndromes with phenomenological and biological charac-

gency Operations Committee (http://coe.jujuy.gob.ar/noticias/). Other

terization that can be further explored.146 By generating high-quality

locations will track as available.

harmonized data across sites we aim to capture both descriptive and,
where possible, causal associations. Notably, even descriptive (rather
than causal) associations will advance our knowledge of post-COVID19 neuropsychiatric manifestations.

2.12
Consortium agreement and data sharing
procedures
The Consortium is led by a steering committee. Multiple subcom-

2.9

Stay-in-touch strategy

mittees address specific areas of focus, including clinical definitions,
epidemiological designs, clinical evaluation, cognitive assessments,

To maintain contact with participants after the initial assessment, we

biomarkers, and neuroimaging. Subcommittees meet ad hoc based on

will use a cell phone–based technology developed by Prof. Sriram Iyen-

specific needs. The entire Consortium meets every fortnight via remote

gar, termed Txt2Info, which provides precision bidirectional mass com-

conferencing. Funding opportunities and publication proposals are dis-

munications during pandemics. Txt2Info combines judicious use of text

cussed in the open meeting, including invitations to collaborate, and

messaging and an easy-to-use REDCap survey instrument in a simple,

interested parties can continue to meet at their discretion. All pro-

lightweight manner. English and Spanish are currently supported, but

tocols, publication drafts, and minutes from subcommittee meetings

other languages can be easily and quickly added. Txt2Info is designed

are made available to all members through a digital board. Each local

to be rapidly customized and deployed for any scenario that requires

site will be led by one to two principal investigators (neurologists, psy-

real-time dissemination of information and community-sourced data

chiatrists, or epidemiologists) and a team of trained clinical research

collection.

associates. A data sharing agreement regulates (and allows collation of)
deidentified results using meta-analytic approaches.

2.10

Determining pre-exposure cognitive status
2.13

Ethical considerations

A key consideration in the recruitment of new cohorts is the assessment of pre-exposure cognitive status because pre-exposure decline

The methods presented here have been approved by several institu-

(even in the absence of a clinical diagnosis of cognitive impairment or

tional review boards and ethics committees affiliated with Consortium

dementia) will result in exclusion from analyses. Because we will be col-

member institutions (University of Texas Health San Antonio, Uni-

lecting new cohorts, we will not have pre-exposure assessments and

versity of Haifa, University of Nottingham, Athens Naval Hospital,

will have to rely on indirect strategies to establish pre-morbid level

Ministry of Health of the Province of Jujuy, Laredo Health Department,

of function. First, we will gather information about the pre-baseline

among many others). The Consortium members will seek and obtain

functional ability of the participant through the WHO SCAN interview.

approval from the corresponding local regulatory institutional boards

Second, where available we will interview a caregiver/informant using

prior to enrolling participants in any cohort and will include specific

the CDR scale or the corresponding section of WHO SCAN. Finally,

informed consent forms for all supplementary data collection, partic-

we will develop cognitive estimates of pre-morbid abilities.147–151

ularly when risks of complications may be somewhat higher such as

These combination methods are necessary because measures typi-

when collecting spinal fluid samples.
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3

DISCUSSION

SCAN is translated into indigenous culture first languages that not
only do not share all of the Western conventional or universal expe-

The research described here aims to provide harmonized method-

riences, but that also place importance on psychological experiences

ologies to better understand whether and how the SARS-CoV-2

that are uncommon outside of that culture.155 While there are use-

pandemic contributes to the risk (and mechanism[s]) of ADRD through

ful structured (e.g., Composite International Diagnostic Interview,

a population-based, quasi-experimental model. Through a global net-

Clinical Interview Schedule–Revised) and semi-structured (e.g., Struc-

work of study teams, we propose to provide a scientific framework to

tured Clinical Interview for the Diagnostic and Statistical Manual of

characterize the neurobehavioral and neuropsychiatric phenomenol-

Mental Disorders, Diagnostic Interview for Genetic Studies) inter-

ogy associated with SARS-CoV-2 in harmonized, multinational, longi-

views and short checklists (e.g., General Anxiety Disorder-7, Patient

tudinal cohorts of post SARS-CoV-2 infection patients. Recruitment

Health Questionnaire-9, Edinburgh Postnatal Depression Schedule) in

is ongoing in several cohorts. We plan to obtain core initial data

widespread use in neuropsychiatry, including clinical trial and epidemi-

within 18 months of recovery from hospital discharge or documented

ological research, these more structured approaches are only capable

infection by PCR. Longitudinal follow-up is proposed at 12 and 24

of identifying established and recognized symptoms, syndromes, and

months after the initial evaluation but with an expectation to extend

predefined disorder categories. This is problematic because novel

the observation of cohorts as long as feasible. An mHealth keeping-

symptoms may prove crucial to tracking and predicting short- and

in-touch process is planned to minimize attrition rates. High rates

longer-term CNS effects of novel viruses, including COVID-19 out-

of mutation in SARS-CoV-2 (https://www.gisaid.org/phylodynamics/

comes. Novel symptom discoveries could also lead to the develop-

global/nextstrain/) strongly suggest that viral infectivity, including neu-

ment of new, more appropriate, brief structured assessments for

rotropism, may not be uniform across countries impacted. However,

wider use.

regardless of the molecular mechanism(s) involved in chronic or progressive injury to the CNS, we assume that the fundamental biology
driving disease development is largely the same across all human

3.2

Minimizing cultural bias

ancestries, even though redundant or parallel processes may result in
diverse pathways leading to the same clinical phenotypes. Conversely,

Cultural variables can also exert a powerful effect on test performance

identical genetic variants may be associated with different pheno-

through construct, method, and item biases,156 but their impact is

types conditioned by the genomic context or ancestry, as well as by

often underestimated. Indeed, the influence of culture on cognition

environmental influences. Therefore, variability, both in the effect of

poses great challenges to cognitive assessments in culturally diverse

genomic variations and in the sources of risk for specific phenotypes,

samples, not the least of which includes the difficulty of responding

is expected to be inherently affected by contexts.152–154 All mem-

to the wide range of cultural contexts, conditions, and circumstances

bers of the Consortium have agreed to share data for meta-analytic

under which testing may occur around the world.156 Thus, while a com-

and replication efforts in the future. Ongoing data collection efforts

mon neuropsychological assessment is an essential component of the

using CNS-SC2 methodology in Argentina, Canada, Cuba, Denmark,

longitudinal assessments planned by the Consortium, we recognized

England, Greece, India, Israel, Sweden, and the United States will pro-

that harmonization of testing procedures across cultures, educational

vide multiple opportunities to attempt replication or expansion of the

attainment levels, languages, and sociocultural environments is a very

findings.

difficult task. Standard cognitive processes are biologically identical for
all humans, but individual, social, and environmental differences may
significantly change the way in which cognitive processes are engaged,

3.1

Detecting novel symptoms

resulting in different patterns of abilities across cultures.157,158 For
instance, studies in Aboriginal peoples show unique approaches to spa-

A critical caveat of this proposal is that the cognitive impairment

tial relationships159 and numerical and memory tasks.160–163 To detect

triggered by SARS-CoV-2 infection may resemble ADRD while differ-

cognitive impairment and cognitive decline therefore requires a basic

ing from it in subtle but important ways. We therefore have chosen

understanding of which skills are needed for normal function in a spe-

clinical assessment, imaging, and biomarker tools that will allow us

cific cultural context.164 Culture-informed adaptations are made to

to detect and describe even subtle differences. The semi-structured

the content and administration of instruments to reflect the experi-

interview WHO SCAN makes use of a conversational interviewing

ences of the population being assessed and to retain within-population

approach, helping patients to describe in their own words their feel-

variance.165

ings, thoughts, and perceptions. The WHO SCAN examiner is trained

The basic idea behind cross-cultural measurement is that the same

to determine which of these verbal and subjective descriptions rep-

aspect of cognitive abilities is assessed similarly in different cultural

resents abnormal psychopathological phenomena (predefined in a

groups using tests selected, optimized, and normed for each individual

glossary of symptom definitions officially endorsed by WHO),125 a

group. In this case, absolute scores would not be directly compara-

technique that lends itself also to describing previously unrecognized

ble across groups, but deviance from norms would be comparable

phenomena or symptoms not catalogued as part of typical syndromes.

regardless of differences that may be present in a variety of impor-

Such novel emerging phenomena are often observed when the WHO

tant background characteristics that vary across and within cultures.
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To address these issues, a panel of experts from across the CNS-SC2

changes in markers of tissue damage in regions functionally connected

Consortium (including key personnel from each continent and with

to the primary olfactory cortex, and reductions in global brain size

expertise in Aboriginal cognitive assessments) worked on harmoniza-

of post-COVID participants even after excluding those who had been

tion of culturally appropriate conceptual tasks (e.g., content, sensitivity,

hospitalized.174 Moreover, infected participants had more cognitive

and face value of the tools) to minimize three key sources of bias:

decline than controls.174 Likely as a consequence of this involvement,

fairness, instrument, and administration. Fairness, understood as equi-

changes in emotional reactivity have been reported as a prominent

table treatment throughout the testing process, refers to the manner in

behavioral change after SARS-CoV-2 infection.

which the tool is administered. Instrument bias refers to all the properties associated with an instrument that are not the target of study but
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3.3

Focus on olfactory impairment

Last, our semi-quantitative neurological examination is primarily
focused on olfactory, motor, and cognitive function. Other aspects of
the clinical examination (i.e., visual and auditory perception, muscle
strength and tone, eye and facial movements, coordination, gait and
balance, and muscular fatigue during 6 minutes of walking) are included
to achieve broad characterization of concomitant complications. There
are multiple sound reasons to pay particular attention to olfactory
deficits in this context. First, increased Aβ burden is correlated with
olfactory impairment in older adults with amnestic MCI,166,167 and
both factors may be predictive of ADRD.166,167 Olfactory impairment is also correlated with tau pathology and neuroinflammation
in patients with ADRD168 and predictive of dementia diagnosis in
several pathologies.36,37 As mentioned in the introduction, SARS-CoV2 invades the olfactory bulb, and this is the likely explanation for
the prevalent anosmia in infected patients.20–22,24–27 This mechanism
has been well established in experimental animals26 and is well supported by imaging studies of sub-acute COVID-19 patients.29–34 Fruit
and flower odor categories have a graded structure that is a universal property retained across categories,169 such that they can be
stably tested. Second, the amygdala is one of the primary connections of the olfactory bulb,170 has among the highest levels of ACE2
expression in the brain,171 is a preferential target of COVID-19 in the
post mortem tissue of patients,172 and is affected in imaging studies
of long COVID patients.173 Most notably, a recent publication from
the UK Biobank found reductions in gray matter thickness and tissue contrast in the orbitofrontal cortex and parahippocampal gyrus;
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